- Generic name
- Sacubitril + Valsartan
- Strength
- 97 mg + 103 mg
- Dosage form
- Tablet
- Manufactured by
- Opsonin Pharma Limited
Arnivas 200 Tablet
About Arnivas 200 97 mg + 103 mg Tablet
Arnivas 200 comes as a tablet with 97 mg + 103 mg of Sacubitril + Valsartan, from Opsonin Pharma Limited. It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Arnivas 200 97 mg + 103 mg Tablet?
Arnivas 200 97 mg + 103 mg tablet is a medicine made by Opsonin Pharma Limited. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. It is used in adults with long-term heart failure and reduced ejection fraction, and in children aged one year and older with symptomatic heart failure. The dose and course are decided by the doctor.
Uses of Arnivas 200
It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Only a qualified doctor can decide if it is suitable for a particular patient. Your doctor will decide if it is suitable for you or your child.
How to use Arnivas 200
The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet with water. Arnivas 200 is taken by mouth. If a dose is missed, ask the doctor or pharmacist for advice. If you miss a dose, ask your doctor or pharmacist what to do. Do not change the dose or stop taking it without speaking to your doctor.
Side effects of Arnivas 200
Common side effects include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough and dizziness. Your doctor may check your kidney function and potassium levels during treatment. Low blood pressure may cause dizziness or fainting, especially when standing up quickly. Tell your doctor straight away if you have trouble breathing, swelling, or feel very dizzy or faint. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Pregnancy and breastfeeding: ask the doctor before use. It is not recommended in severe liver impairment. This medicine is not recommended during pregnancy because it may harm the unborn baby. Tell your doctor about kidney or liver problems, low blood pressure, or other medicines you take, including potassium-sparing diuretics, NSAIDs and lithium.
Frequently asked questions
What is Arnivas 200 used for?
It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Only a qualified doctor can decide if it is suitable for a particular patient.
How should I take Arnivas 200?
The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet with water.
What are the side effects of Arnivas 200?
Common side effects include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough and dizziness. Your doctor may check your kidney function and potassium levels during treatment.
Is Arnivas 200 safe for everyone?
Pregnancy and breastfeeding: ask the doctor before use. It is not recommended in severe liver impairment.
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ... Read more
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
Dosage & Administration
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Recommended Dose Titration-
Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
Pregnancy & Lactation
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Storage Conditions
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.